Matching trials
2,411 results
- SPARCIndependent statistical analysis of Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- SPARKIndependent statistical analysis of Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- SPARK2Independent statistical analysis of Phase 2B Study Assessing Pain Relief After Replacement of the Knee: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SPOTLIGHT203Independent statistical analysis of BO-112 With Pembrolizumab in Unresectable Malignant Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04570332).
- STANDUP AHFIndependent statistical analysis of Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- STAR-TRECIndependent statistical analysis of STAR-TREC (NCT02945566), a randomized phase 2/3 trial evaluating organ preservation strategies versus total mesorectal excision for early rectal cancer.
- STARSIndependent statistical analysis of A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- STARTIndependent statistical analysis of Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02097641).
- STARTRK-NGIndependent statistical analysis of STARTRK-NG (NCT02650401), a phase 1/2 study of entrectinib in children and adolescents with locally advanced or metastatic solid tumors and CNS tumors.
- STEP 210Independent statistical analysis of Multicenter, Open-label, Safety and Tolerability Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01649557).
- STOICIndependent statistical analysis of the randomized phase 2 STOIC trial evaluating budesonide dry powder inhaler in coronavirus infection, including trial design, the primary endpoint, planned statistical analysis, and interpretation.
- STOMPIndependent statistical analysis of STOMP (NCT02343042), a randomized phase 1/2 study evaluating selinexor with backbone treatments in patients with multiple myeloma, including dose-escalation, pharmacokinetic, response, and duration-of-response endpoints.
- STORMIndependent statistical analysis of the STORM phase 2 trial of selinexor and dexamethasone in multiple myeloma, including its non-randomized design, overall response rate endpoint, statistical methodology, and safety reporting.
- SUN1058Independent statistical analysis of A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone: primary endpoint results, effect estimate with confidence interval,…
- SUPERNOVAIndependent statistical analysis of the randomized phase 2/3 SUPERNOVA trial of AZD3152 and AZD7442 for prevention of COVID-19, including non-inferiority, superiority, Poisson regression, ANOVA, safety, and interpretation of reported results.
- SURPHIndependent statistical analysis of A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SWARM-PaIndependent statistical analysis of Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis: primary endpoint results, effect estimate with confidence…
- T1GERIndependent statistical analysis of A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- TAPERIndependent statistical analysis of Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal: primary endpoint results, effect estimate with confidence interval,…
- TARGETIndependent statistical analysis of Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TASCO1Independent statistical analysis of TASCO1 (NCT02743221), a randomized phase 2 study comparing trifluridine/tipiracil plus bevacizumab with capecitabine plus bevacizumab in previously untreated metastatic colorectal cancer patients non-eligible for intensive therapy.
- TAXYNERGYIndependent statistical analysis of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC): primary endpoint results, effect estimate with…
- TAZPOWERIndependent statistical analysis of A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- TEAMIndependent statistical analysis of A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TeenCoveComplete statistical analysis of the TeenCove trial of mRNA-1273 and mRNA-1273.222 in adolescents 12 to
- TheraPAn independent statistical analysis of the TheraP randomized phase 2 trial of 177Lu-PSMA617 versus cabazitaxel in progressive metastatic castration resistant prostate cancer, including trial design, PSA response endpoint, planned statistical analysis, and…
- TIDE-asthmaIndependent statistical analysis of Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- TitAINIndependent statistical analysis of A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- TK112690Independent statistical analysis of Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- TNBCIndependent statistical analysis of Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TOP 1501Independent statistical analysis of Neoadjuvant Pembrolizumab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02818920).
- TOP1201 IPIIndependent statistical analysis of Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence…
- TOPASIndependent statistical analysis of Evaluation of Outcomes of Restoring Pelvic Floor Support With TOPAS in Women With Moderate Fecal Incontinence Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- TRAILIndependent statistical analysis of Letrozole for Lymphangioleiomyomatosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01353209).
- TRAIL1An independent statistical analysis of TRAIL1, a randomized phase 2 study of pirfenidone versus placebo in patients with rheumatoid arthritis interstitial lung disease, including the composite FVC-or-death endpoint and its statistical interpretation.
- TRANQUILITYIndependent statistical analysis of A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- TREAT-COVIDIndependent statistical analysis of TREAT-COVID (NCT04351516), a randomized phase 2/3 trial evaluating hydroxychloroquine versus placebo in older adults with COVID-19. Includes trial design, endpoints, planned methodology, and statistical interpretation.
- TremelimumabIndependent statistical analysis of Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- TRINITI-1An independent statistical analysis of TRINITI-1, evaluating ribociclib with everolimus and exemestane in HR+ HER2- locally advanced or metastatic breast cancer after progression on a CDK 4/6 inhibitor.
- Tx-TreatmentIndependent statistical analysis of Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Tysabri JapanIndependent statistical analysis of Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- UGIH09067Independent statistical analysis of Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Unite-CNMIndependent statistical analysis of Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- VALENTINOAn educational statistical analysis of the VALENTINO phase 2 randomized trial of panitumumab-based maintenance in patients with metastatic colorectal cancer, covering its design, progression-free survival endpoint, planned analysis, statistical methods, and interpretation.
- VC01-103Independent statistical analysis of A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- VELVETIndependent statistical analysis of A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor…
- VERONICAIndependent statistical analysis of the VERONICA phase 2 trial comparing venetoclax plus fulvestrant with fulvestrant in women with ER-positive, HER2-negative locally advanced or metastatic breast cancer after CDK4/6 inhibitor therapy.
- VICARESIndependent statistical analysis of A Study Evaluating ClariVein With a Sclerosing Agent for the Treatment of Venous Insufficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- VISSITIndependent statistical analysis and educational interpretation of VISSIT (NCT00816166), a randomized phase 2/3 trial of the Pharos Vitesse Neurovascular Stent System plus medical therapy versus medical therapy for ischemic stroke and transient…
- Vita-ShockIndependent statistical analysis of Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02786498).